Stoke Therapeutics, Inc. (STOK) Tops Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Join SI Premium – FREE
Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.47), $0.07 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.89 million versus the consensus estimate of $3.64 million.
For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
- Jefferies Financial Group (JEF) Misses Q2 EPS by 22c
- Barclays Downgrades Brown Forman (BF-B) to Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
